Stopping GLP-1s May Lead to Weight Regain In Less Than 2 Years, Review Finds
Research shows that people who stop taking GLP-1 medications regain weight within 2 years. Image Credit: Tatsiana Volkava/Getty Images
A new study has found that people regain weight within 2 years of stopping a GLP-1 drug.
Metabolic improvements also tend to fade within that time, researchers found.
Experts advise that slowly tapering off the medication is better than quitting abruptly.
Tirzepatide, Hormone Therapy May Aid Weight Loss After Menopause
A combination of hormone therapy and the GLP-1 drug tirzepatide may promote weight loss in postmenopausal females. Image Credit: Mauro Grigollo/Stocksy
A new study found that postmenopausal females who use hormone therapy in combination with tirzepatide experience greater weight loss compared to those who don’t.
Tirzepatide (Zepbound) is an FDA-approved medication prescribed for weight loss. It’s also the active ingredient in the GLP-1 medication Mounjaro to treat type 2 diabetes.
Oral Semaglutide Lowers Heart Failure Risk in People with Type 2 Diabetes
Emerging evidence suggests that oral semaglutide may reduce the risk of heart failure–related events in people with type 2 diabetes. JasonDoiy/Getty Images
Oral semaglutide may reduce heart failure events in high-risk individuals with type 2 diabetes.
The benefit appeared strongest among those with a common but hard-to-treat form of heart failure.
Type 2 diabetes and heart disease often co-occur and the findings could pave the way for new treatments.
Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue Up 46% in Q4
Mounjaro and Zepbound combined for $11.7 billion in the fourth quarter, which beat analyst consensus of $10.6 billion.
Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio
Novo Nordisk is looking into acquiring or developing a long-acting GLP-1 drug that could compete with Pfizer’s monthly obesity shot.
Pfizer beat Novo in the ferocious battle to acquire …
GLP-1 obesity drugs can complicate life for people with disordered eating
Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with eating disorders.
More GLP-1 Drug Lawsuits; Military’s Rising Obesity Rates; Male Birth Control Soon?
(MedPage Today) — More lawsuits are alleging that patients are not being sufficiently warned of certain severe injuries associated with GLP-1 receptor agonists. (USA Today)
Meanwhile, the U.K.’s Medicines and Healthcare Products Regulatory Agency…
Rethinking weight loss in the Ozempic era: Researchers urge a more holistic view
In the world of obesity research, the arrival of GLP-1 drugs like Ozempic feels seismic. At a recent conference, Martin Binks, a leader in obesity research, found himself marveling with a colleague: “Can you believe we finally reached this moment, that we lived long enough to see this?”
Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA PF’3944 Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
NEW YORK–(BUSINESS WIRE) February 03, 2026 — Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1…
STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition
Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.